Literature DB >> 19393510

Brimonidine and apraclonidine as vasoconstrictors in adjustable strabismus surgery.

Annegret H Dahlmann-Noor1, Edel Cosgrave, Stuart Lowe, Maryse Bailly, Anthony J Vivian.   

Abstract

INTRODUCTION: Conjunctival and episcleral bleeding can interfere with visualization of anatomic structures during strabismus surgery. In the United Kingdom, dilute adrenaline (epinephrine) is routinely used to induce vasoconstriction at the beginning of strabismus surgery. Because it causes mydriasis and mildly inhibits accommodation, it is relatively contraindicated if early postoperative suture adjustment is planned.
PURPOSE: To test whether topical alpha(2)-adrenergic agonists (brimonidine 0.2% and apraclonidine 1%) are useful alternatives to topical adrenaline (epinephrine) in adjustable suture strabismus surgery.
METHODS: Prospective observational pilot study. Brimonidine 0.2% or apraclonidine 1% was applied to the medial or lateral conjunctiva of 10 consecutive adult patients undergoing strabismus surgery with adjustable sutures under general anesthesia. Video images were taken before and up to 20 minutes after instillation. The surface area of ocular surface blood vessels on the acquired images was quantified at selected intervals using imaging software.
RESULTS: Both agents induced potent transient vasoconstriction of ocular surface vessels. Within 5 minutes of application, brimonidine reduces blood vessel surface area by 69.2% (95% CI, 50.4-88); this effect persists for 20 minutes. Apraclonidine reduces vessel area by 64.6% (95% CI, 57.2%-72%) within 10 minutes and begins to wear off over the following 10 minutes.
CONCLUSIONS: Both brimonidine and apraclonidine may be useful alternatives to topical adrenaline (epinephrine) in adjustable suture strabismus surgery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19393510     DOI: 10.1016/j.jaapos.2008.12.001

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  4 in total

1.  Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial.

Authors:  Eugene McLaurin; Megan E Cavet; Paul J Gomes; Joseph B Ciolino
Journal:  Optom Vis Sci       Date:  2018-03       Impact factor: 1.973

2.  Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials.

Authors:  Stacey L Ackerman; Gail L Torkildsen; Eugene McLaurin; Jason L Vittitow
Journal:  Clin Exp Optom       Date:  2018-12-07       Impact factor: 2.742

3.  Prophylactic effect of brimonidine to minimize the incidence of subconjunctival hemorrhage in the early postoperative period after 23G pars plana vitrectomy.

Authors:  Mari Carmen Desco; Julio Cesar Molina Martín; Jorge Mataix-Boronat; Isabel Pascual-Camps; Elena Palacios-Pozo; Marisa Barón-García; David P Piñero; Amparo Navea-Tejerina
Journal:  Ther Adv Ophthalmol       Date:  2021-10-05

4.  Effect of Topical Brimonidine 0.15% on Conjunctival Injection after Strabismus Surgery in Children.

Authors:  Dong Hyun Kim; Hee Kyung Yang; Sang Beom Han; Jeong-Min Hwang
Journal:  J Ophthalmol       Date:  2021-05-04       Impact factor: 1.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.